Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Eur J Cancer Care (Engl) ; 24(1): 117-24, 2015.
Article in English | MEDLINE | ID: mdl-25848698

ABSTRACT

We performed a retrospective study to analyse the characteristics and clinical outcomes of diffuse large B-cell lymphoma (DLBCL) patients with hepatitis B virus (HBV) infection and compare with those without HBV infection. The occurrence of hepatitis after withdrawal of prophylactic antiviral treatment on completion of chemotherapy was also assessed. The HBsAg-positive patients were given prophylactic antiviral treatment until 6 months after finishing chemotherapy. A total of 81 patients were recruited with 16 in the HBsAg-positive group and 65 in the HBsAg-negative group. The clinical characteristics were similar in both groups of patients. There was no significant difference in complete remission rate between the two groups (63% in HBsAg-positive group vs. 54% in HBsAg-negative group, P = 0.59). There was also no statistically significant difference in overall survival between the two groups (P = 0.23). Four of the 16 HBsAg-positive patients (25%) had hepatitis after cessation of chemotherapy and prophylactic lamivudine. The mean time of onset of hepatitis was 3 months after stopping lamivudine. In conclusion, HBV infection did not appear to affect the prognosis of DLBCL patients given antiviral prophylaxis. It is reasonable to consider prophylactic antiviral therapy to extend to at least one year on completion of chemotherapy.


Subject(s)
Anti-HIV Agents/therapeutic use , Hepatitis B/complications , Lamivudine/therapeutic use , Lymphoma, Large B-Cell, Diffuse/complications , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols , Female , Hepatitis B/prevention & control , Hepatitis B virus/isolation & purification , Humans , Lymphoma, Large B-Cell, Diffuse/drug therapy , Male , Middle Aged , Prognosis , Retrospective Studies , Risk Factors , Rituximab/adverse effects , Rituximab/therapeutic use , Survival Analysis , Treatment Outcome , Young Adult
4.
Mar Pollut Bull ; 66(1-2): 158-63, 2013 Jan 15.
Article in English | MEDLINE | ID: mdl-23177239

ABSTRACT

Global marine vessels emissions are adversely affecting human health particularly in southeast Asia. But health burdens from both ocean- and river-going vessels in Pearl River Delta (PRD) regions are not quantified. We estimated the potential health impacts using pooled relative risks of mortality and hospital admissions in China, and the model derived concentrations of sulfur dioxide (SO2), particulate matter (PM10), nitrogen dioxide (NO2) and ozone (O3) due to vessels emissions. SO2 concentrations due to marine emissions in Hong Kong were 13.6 µg m⁻³ compared with 0.7 µg m⁻³ in PRD regions that were far from the marine vessels. In PRD regions, the estimated annual numbers (per million people) of excess deaths from all natural causes and hospital admissions from cardiorespiratory causes attributable to SO2, NO2, O3 and PM10 combined from marine emissions were 45 and 265 respectively. Marine emission control measures could contribute a large reduction in mortality and hospital admissions in PRD regions especially in Hong Kong.


Subject(s)
Air Pollutants/analysis , Air Pollution/statistics & numerical data , Environmental Monitoring/methods , Health Impact Assessment , China , Humans , Nitrogen Dioxide/analysis , Ozone/analysis , Particulate Matter/analysis , Rivers , Sulfur Dioxide/analysis
5.
Hong Kong Med J ; 18 Suppl 2: 8-11, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22311353

ABSTRACT

1. Using a common modelling approach, mortality attributable to influenza was higher in the two subtropical cities Guangzhou and Hong Kong than in the tropical city Singapore. 2. The virus activity appeared more synchronised in subtropical cities, whereas seasonality of influenza tended to be less marked in the tropical city. 3. High temperature was associated with increased mortality after influenza infection in Hong Kong, whereas relative humidity was an effect modifier for influenza in Guangzhou. No effect modification was found for Singapore. 4. Seasonal and environmental factors probably play a more important role than socioeconomic factors in regulating seasonality and disease burden of influenza. Further studies are needed in identifying the mechanism behind the regulatory role of environmental factors.


Subject(s)
Influenza, Human/mortality , Myocardial Ischemia/mortality , Pneumonia/mortality , Pulmonary Disease, Chronic Obstructive/mortality , Aged , Cause of Death , Hong Kong/epidemiology , Humans , Humidity , Influenza A Virus, H1N1 Subtype , Influenza A Virus, H3N2 Subtype , Influenza, Human/complications , Myocardial Ischemia/complications , Pneumonia/complications , Poisson Distribution , Pulmonary Disease, Chronic Obstructive/complications , Seasons , Singapore/epidemiology , Temperature
6.
Singapore Med J ; 52(9): e184-6, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21947161

ABSTRACT

Radiosynovectomy is a local and minimally invasive radiotherapy for treating various chronic inflammatory arthritis such as rheumatoid arthritis, osteoarthritis and haemophilic arthropathy. In haemophilic arthropathy, it reduces the frequency of haemarthrosis and delays the development of severe joint destruction, which ultimately requires surgical intervention. Its role in warfarin-related haemarthrosis is less clear. Haemarthrosis is an uncommon complication of warfarin use, and anticoagulation may need to be discontinued. We describe yttrium-90 radiosynovectomy use in a 74-year-old man with underlying ischaemic heart disease, atrial fibrillation, previous embolic stroke and recurrent haemarthrosis of an osteoarthritic right knee. Anticoagulation was vital and could not be permanently stopped. Due to continuing anticoagulation, he had multiple hospitalisations with recurrent right knee haemarthrosis. Intraarticular right knee yttrium-90 citrate colloid injection led to a cessation of haemarthrosis for eight months. We examined the available literature for the role of radiosynovectomy in such circumstances.


Subject(s)
Hemarthrosis/chemically induced , Hemarthrosis/complications , Osteoarthritis/complications , Radiotherapy/methods , Warfarin/adverse effects , Aged , Hemarthrosis/radiotherapy , Humans , Knee/pathology , Knee Joint/radiation effects , Magnetic Resonance Imaging/methods , Male , Myocardial Ischemia/complications , Stroke/complications , Synovial Fluid/metabolism , Yttrium Radioisotopes/pharmacology
7.
Int J Environ Health Res ; 19(3): 175-85, 2009 Jun.
Article in English | MEDLINE | ID: mdl-20183191

ABSTRACT

Many epidemiological investigations indicate that excess risks of mortality and morbidity may vary among specific PM(2.5) components. Nickel (Ni) and vanadium (V) particulate metal species may potentially be related to increasing respiratory and cardiovascular mortality and morbidity. This review focuses on exposure concentrations of these two species in various settings, their health effects based on epidemiological and toxicological studies and the underlying mechanisms. The evidence shows that environmental exposure concentrations of Ni and V in general setting are lower than the World Health Organization standard (V, 1 microg/m(3)/day) in 2000, or the European Environment Agency standard (Ni, 1 microg/m(3)/day) in 2003, but their associations with cardiopulmonary diseases can still be found. The toxicological mechanism can be explained by laboratory-based studies. Updated safe guidelines on environmental and human exposure of Ni and V are necessary in order to clarify the associations between them and cardiopulmonary diseases and provide environmental intervention policies.


Subject(s)
Air Pollutants/toxicity , Cardiovascular System/drug effects , Environmental Exposure/adverse effects , Nickel/toxicity , Particulate Matter/toxicity , Respiratory System/drug effects , Vanadium/toxicity , Air Pollutants/adverse effects , Environmental Exposure/legislation & jurisprudence , Environmental Exposure/prevention & control , Humans , Nickel/adverse effects , Nickel/standards , Particulate Matter/adverse effects , Vanadium/adverse effects
8.
J Interferon Cytokine Res ; 20(9): 787-94, 2000 Sep.
Article in English | MEDLINE | ID: mdl-11032398

ABSTRACT

Retinoic acid (RA) can potentiate the antitumor effect of interferons (IFN) in a variety of tumor types, including renal cell carcinoma (RCC). The mechanisms by which RA and IFN increase the antitumor effects in RCC are unknown. We used growth assays and mobility shift assays to examine the effects of combining 13-cis-retinoic acid (CRA) and IFN-alpha (plus IFN-gamma) on proliferation and on the expression of the IFN-specific transcription factor IFN-stimulated gene factor 3 (ISGF3) in RCC cell lines. Combining CRA and IFN-alpha resulted in a significant increase in growth inhibition in four cell lines compared with IFN-alpha or CRA alone. Binding of nuclear extracts from RCC cells to an IFN-stimulated response element (ISRE) oligonucleotide probe following incubation with IFN-alpha was not increased by CRA but was significantly increased by pretreatment by IFN-gamma in a time-dependent fashion. Proliferation assays showed that sequential addition of IFN-gamma and IFN-alpha significantly increased growth inhibition. IFN-alpha but not IFN-gamma or CRA increased the cellular levels Stat2 and p48 but not Statl. IFN-gamma pretreatment enhanced the upregulation of p48 levels by IFN-alpha. Combining RA and IFN results in additive growth inhibition on RCC cell lines. This increase in growth inhibition is not mediated by increased ISGF3 expression.


Subject(s)
Antineoplastic Agents/pharmacology , Interferon-alpha/pharmacology , Tretinoin/pharmacology , Carcinoma, Renal Cell/pathology , Cell Division/drug effects , Drug Interactions , Drug Synergism , Humans , Interferon-gamma/pharmacology , Isotretinoin/pharmacology , Kidney Neoplasms/pathology , Signal Transduction/drug effects , Tumor Cells, Cultured
9.
Oncogene ; 19(13): 1623-34, 2000 Mar 23.
Article in English | MEDLINE | ID: mdl-10763819

ABSTRACT

The majority of the promyelocytic leukemia (PML) protein is present in nuclear bodies which are altered in several pathogenic conditions including acute promyelocytic leukemia. PML nuclear bodies are found in nearly all cells yet their function remains unknown. Here, we demonstrate that PML and the eukaryotic initiation factor 4E (elF-4E) co-localize and co-immunopurify. eIF-4E is involved in nucleocytoplasmic transport of specific mRNAs including cyclin D1. eIF-4E overexpression leads to increased cyclin D1 protein levels; whereas, overexpression of PML leads to decreased cyclin D1 levels. Neither PML nor eIF-4E cause significant changes in cyclin D1 mRNA levels. The association with eIF-4E led us to investigate if PML could alter mRNA distribution as a possible post-transcriptional mechanism for suppressing cyclin D1 production. We show that overexpression of PML results in nuclear retention of cyclin D1 mRNA and that intact PML nuclear bodies are required. Addition of eIF-4E overcomes PML induced retention and alters the morphology of PML bodies suggesting a mechanism by which eIF-4E can modulate PML function. These results raise the possibility that PML nuclear bodies may participate in the regulation of nucleocytoplasmic transport of specific mRNAs.


Subject(s)
Cyclin D1/biosynthesis , Cytoplasm/chemistry , Leukemia, Promyelocytic, Acute/metabolism , Neoplasm Proteins/physiology , Nuclear Proteins , RNA, Messenger/metabolism , RNA, Neoplasm/metabolism , Transcription Factors/physiology , 3T3 Cells , Animals , Biological Transport , Cell Line , Cyclin D1/genetics , Eukaryotic Initiation Factor-4E , Fibroblasts , Humans , Leukemia, Promyelocytic, Acute/genetics , Leukemia, Promyelocytic, Acute/pathology , Macromolecular Substances , Mice , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/chemistry , Neoplasm Proteins/genetics , Neoplasm Proteins/isolation & purification , Organelles/chemistry , Organelles/physiology , Peptide Initiation Factors/analysis , Peptide Initiation Factors/isolation & purification , Promyelocytic Leukemia Protein , Protein Structure, Tertiary , Recombinant Fusion Proteins/physiology , Subcellular Fractions/chemistry , Transcription Factors/chemistry , Transcription Factors/isolation & purification , Transcription, Genetic , Transfection , Tumor Suppressor Proteins
10.
Anticancer Res ; 18(1A): 1-7, 1998.
Article in English | MEDLINE | ID: mdl-9568047

ABSTRACT

BACKGROUND: Alpha interferon (IFN-alpha) is commonly used to treat patients with advanced renal cell carcinoma (RCC). We previously reported that resistance of RCCs to IFN-alpha in vitro correlated with the expression of a cell-surface glycoprotein of 160,00 kD molecular weight (gp160) which we subsequently identified as aminopeptidase A. MATERIALS AND METHODS: To directly test the role of gp160/APA in IFN-resistance, we stably introduced the gp160/APA cDNA into IFN-sensitive SK-RC-49 cells resulting in the expression of an enzymatically active gp160/APA protein. In addition, to determine if gp160/APA expression could function as a marker of IFN-resistance in vivo, we assessed gp160/APA protein levels in autologous normal kidney and primary renal cancer specimens from 29 patients half of which were randomized to receive adjuvant IFN-alpha therapy following nephrectomy. RESULTS: Four clones which possessed varying amounts of gp160/APA specific enzyme activity were assayed for sensitivity to the antiproliferative effects of IFN-alpha. All four clones exhibited sensitivity to IFN-alpha similar to that observed with parental SK-RC-49 cells. The analysis of tumor tissue detected no significant difference between the mean level of gp160/APA in tissue from control and IFN-alpha treated patients (1.33 A.U. versus 0.9981 A.U., p = 0.23); however, the mean gp160/APA level was significantly less in tumor tissue (mean = 1.15 A.U.) compared to normal tissue (mean = 2.15 A.U.; p < 0.00001). Within the IFN-alpha treated group, tumor gp160/APA levels did not correlate with the development of metastases or survival (p = 0.469). CONCLUSIONS: These data indicate that gp160/APA does not directly convey IFN-resistance to RCC cells and suggest that expression of gp160/APA in primary RCCs does not predict the benefit of IFN-alpha therapy.


Subject(s)
Aminopeptidases/metabolism , Carcinoma, Renal Cell/immunology , Interferon-alpha/pharmacology , Kidney/immunology , Aged , Antineoplastic Agents/pharmacology , Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/enzymology , Cell Differentiation , Cell Line , Drug Resistance , Female , Glutamyl Aminopeptidase , Growth Inhibitors/pharmacology , Humans , Interferon alpha-2 , Interferon-alpha/therapeutic use , Kidney/enzymology , Kidney Neoplasms/drug therapy , Kidney Neoplasms/enzymology , Kidney Neoplasms/immunology , Male , Middle Aged , Recombinant Proteins , Transfection , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...